BMY

Bristol Myers Squibb Company: Too Cheap To Ignore | FAST Graphs

Bristol Myers Squibb A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market. However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but …

FAST Graphs Analyze out Loud Video Bristol-Myers Squibb

Introduction Many of you, if you follow Bristol-Myers Squibb, all know that they recently merged with Celgene and they’ve now become a much bigger company.  What’s been happening in big pharma, even the big names like Merck and Pfizer, these were very strong growth stocks years ago, but in more recent times their growth has …

Subscriber Request Series: Celgene Corp (NAS:CELG) and Bristol Myers (NYS:BMY)

FAST Graphs Analyze Out Loud Celgene Corp $CELG: Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and …

6 High Yield Pharmaceutical Companies: Do They Justify the Risk?

Introduction Today Investors are keenly focused on income while simultaneously very risk averse.This current behavior brings with it a level of frustration.The appetite for yield is high precisely at a time when yields on the traditionally safest investments like bonds and CDs, etc. are at historic lows.On the other hand, dividend yields on many blue-chip …